Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Sanjivani Paranteral Ltd (531569)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531569 NSE: Pharmaceuticals & Drugs | Small Cap | Sanjivani Paranteral Share Price
₹173.55 5.90 (3.52%)
As on 04-Nov'26 16:59
Sanjivani Paranteral Ltd (531569)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531569 NSE: Pharmaceuticals & Drugs | Small Cap | Sanjivani Paranteral Share Price
₹173.55 5.90 (3.52%)
As on 04-Nov'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹206 Cr.
Current Price
₹173.6
52-Week Low / High
₹126 / 244
TTM EPS
₹6.1
TTM Sales
₹74.6 Cr.
Book Value per Share
₹41.3
P/E Ratio
27.58
Higher than its 5-year historical median
Industry PE
52.9
Price to Book (P/B)
4.06
Lower than its 5-year historical median
Price to Sales (P/S)
2.76
Lower than its 5-year historical median
EV/EBITDA
16.79
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
15.77%
Outperforms industry median
Return on Capital Employed (ROCE)
18.48%
Outperforms industry median
Return on Assets (ROA)
8.06%
Outperforms industry median
Operating Profit Margin
15%
Outperforms industry median
Net Profit Margin
9.75%
Outperforms industry median
Gross Profit Margin
15.5%
Outperforms industry median
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-7.62%
Operating Profit Growth (1 Year)
-
-1.07%
Net Profit Growth (1 Year)
-
-17.31%
Asset Quality
Promoter Holding
31.56%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹38 Cr.
Equity
₹12.3 Cr.
Face Value
₹10
All Time Low / High
₹1.76 / 396.95
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Sanjivani Paranteral Ltd a good quality company?
Sanjivani Paranteral Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Sanjivani Paranteral Ltd performance compare with that of its Peers?
Revenue growth of Sanjivani Paranteral Ltd vs industry peers?
Sanjivani Paranteral Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 0.00%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Sanjivani Paranteral Ltd?
Promoters hold 31.56% of the Sanjivani Paranteral Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Sanjivani Paranteral Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 23% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sanjivani Paranteral Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -33% | -227.3% | 0% | -266% | 266.4% | 0% | 0% | 55.3% | 30.2% | 19.3% | - |
| Value Creation Index ⓘ | NA | NA | NA | NA | 18.0 | NA | NA | 3.0 | 1.2 | 0.4 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 32.7 | 18 | 25.1 | 16.4 | 25.1 | 30.6 | 35.5 | 54.4 | 70.1 | 64.8 | 66 |
| Sales YoY Gr. | - | -45% | 39.7% | -34.8% | 53.4% | 22% | 15.9% | 53.3% | 28.8% | -7.6% | - |
| Adj EPS ⓘ | -46 | -90 | -3.7 | -3.2 | 1.5 | 4.7 | 4.2 | 5 | 6.4 | 5.1 | 6.1 |
| YoY Gr. | - | NA | NA | NA | NA | 214.8% | -10.9% | 20.3% | 26.4% | -19.7% | - |
| BVPS (₹) ⓘ | -14.8 | -89.6 | -80 | -82.9 | -52.8 | -7.6 | -3.1 | 22.1 | 30.8 | 39.4 | 41.3 |
| Adj Net Profit ⓘ | -27.2 | -53.1 | -2.2 | -1.9 | 1.3 | 4.7 | 4.2 | 5.9 | 7.6 | 6.3 | 7 |
| Cash Flow from Ops. ⓘ | 9.6 | 3.1 | 2.5 | -0.2 | 0.6 | 8.5 | 4.7 | -10.7 | -0.2 | -1.6 | - |
| Debt/CF from Ops. ⓘ | 6.3 | 15.8 | 19.4 | -280.1 | 79 | 0.7 | 0.5 | -0.1 | -23.6 | -5.9 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 7.9% | 20.9% | 22.2% | -7.6% | ||||
| Adj EPS ⓘ | NA | 28% | 6.9% | -19.7% | ||||
| BVPSⓘ | NA | NA | NA | 27.7% | ||||
| Share Price | 23.4% | 48.5% | 11.7% | -18.3% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -618.2 | 172.5 | 4.4 | 3.9 | -2.7 | -17.9 | -78.4 | 47.3 | 23 | 14.5 | 15.1 |
| Op. Profit Mgn % ⓘ | -70.4 | -289.8 | -7 | -3.4 | 8.5 | 13.9 | 14.8 | 14.7 | 14.7 | 14.7 | 15.3 |
| Net Profit Mgn % ⓘ | -83.1 | -295.5 | -8.7 | -11.3 | 5.1 | 15.3 | 11.8 | 10.8 | 10.8 | 9.7 | 11.3 |
| Debt to Equity ⓘ | -6.9 | -0.9 | -1 | -1 | -1 | -0.8 | -0.8 | 0 | 0.2 | 0.2 | - |
| Working Cap Days ⓘ | 722 | 649 | 171 | 179 | 133 | 128 | 121 | 124 | 166 | 251 | 150 |
| Cash Conv. Cycle ⓘ | 567 | 420 | -105 | -169 | -112 | -90 | -82 | 0 | 32 | 42 | 94 |
Valuation of Sanjivani Paranteral - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|
| Sales | 54 | 70 | 69 |
| Operating Expenses ⓘ + | 46 | 60 | 58 |
| Operating Profit ⓘ | 8 | 10 | 10 |
| Operating Profit Margin (%) | 14.7% | 14.7% | 14.8% |
| Other Income ⓘ + | 1 | 1 | 1 |
| Interest ⓘ | 0 | 1 | 1 |
| Depreciation ⓘ | 1 | 1 | 1 |
| Profit Before Tax ⓘ | 8 | 10 | 9 |
| Tax ⓘ | 1 | 2 | 3 |
| Profit After Tax | 6 | 8 | 7 |
| PAT Margin (%) | 11.3% | 11.6% | 9.8% |
| Adjusted EPS (₹) | 5.3 | 6.8 | 5.5 |
| Dividend Payout Ratio (%) | 0% | 7.30% | 0% |
| PARTICULARS | Mar'24 | Mar'25 | Mar'26 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 26 | 37 | 48 | ||||||||
| Debt + | 1 | 5 | 10 | ||||||||
| Minority Interest | 0 | 2 | 3 | ||||||||
| Trade Payables | 6 | 15 | 4 | ||||||||
| Others Liabilities ⓘ | 11 | 19 | 23 | ||||||||
| Total Liabilities ⓘ | 43 | 78 | 88 | ||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 10 | 21 | 47 | ||||||||
| CWIP ⓘ | 0 | 19 | 1 | ||||||||
| Investments ⓘ | 0 | 0 | 1 | ||||||||
| Inventories | 10 | 11 | 11 | ||||||||
| Trade Receivables | 5 | 17 | 15 | ||||||||
| Cash Equivalents | 10 | 2 | 1 | ||||||||
| Others Assets ⓘ | 9 | 9 | 11 | ||||||||
| Total Assets ⓘ | 43 | 78 | 88 | ||||||||
| PARTICULARS | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -11 | 12 | -0 |
| Cash Flow From Investing Activity ⓘ + | -12 | -22 | -10 |
| Cash Flow From Financing Activity ⓘ + | 23 | 10 | 10 |
| Net Cash Flow ⓘ | 0 | 1 | -0 |
| PARTICULARS | Mar'24 | Mar'25 | Mar'26 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 23.83 | 25.9 | 15.77 | |||||||
| ROCE (%) | 27.11 | 29.18 | 18.48 | |||||||
| Asset Turnover Ratio | 1.26 | 1.2 | 0.83 | |||||||
| PAT to CFO Conversion(x) | -1.83 | 1.5 | -0 | |||||||
| Working Capital Days | ||||||||||
| Receivable Days | 31.40 | 53.70 | 85.30 | |||||||
| Inventory Days | 65.20 | 50.80 | 57.20 | |||||||
| Payable Days | 73.60 | 94.70 | 78.40 | |||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Annual reports
No annual reports available.
Concalls
No concalls available.
Sanjivani Paranteral Ltd FAQs
The current trading price of Sanjivani Paranteral on 04-Nov-2026 16:59 is ₹173.6.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Nov-2026 the market cap of Sanjivani Paranteral stood at ₹205.9 Cr
The latest P/E ratio of Sanjivani Paranteral as of 03-Nov-2026 is 27.51.
The latest P/B ratio of Sanjivani Paranteral as of 03-Nov-2026 is 4.06.
The 52-week high of Sanjivani Paranteral is ₹244.0 and the 52-week low is ₹126.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sanjivani Paranteral is ₹66.33 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Sanjivani Paranteral Ltd is a below average quality company.
The key valuation ratios of Sanjivani Paranteral Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sanjivani Paranteral Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Sanjivani Paranteral Ltd
Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company’s products includes oral solids, small volume parenterals and sterile powder formulations.
The company has grown many folds and aspires to be a respected research-based company. With its diverse product portfolio, it is rapidly expanding its reach to the global marketplace, riding on its success in India and in the world’s emerging and developed markets.
After establishing itself in India, Sanjivani has extended its reach globally by entering the markets of Asia, Europe, Africa and Latin America. The company has active presence in countries like Russia, Ukraine, Uzbekistan, Turkmenistan, Fiji, Vietnam, Sri Lanka, Nepal, Malaysia, Thailand, Nigeria and Peru, to name a few. Sanjivani Parenteral has also got its plant approved by the registration authorities of Congo, Sudan and Sri Lanka. It is making its presence felt in the world market now, through leveraging its manufacturing capacity, quality of products and international alliances.
International business contributes about 30% of the company’s revenue and is set to grow to more than 50% in the coming two years. This includes the sales of Sanjivani’s own brands and the revenue from the contract manufacturing services that the company provides to its overseas clients. The company is in the making of a strong base to broaden its horizons.
Sanjivani has been a regular supplier to the armed forces’ hospitals in India. Furthermore, many government and private hospitals have availed of the products and services offered by Sanjivani across the country. The company also has its own marketing operations in India and boasts of over 1000 distributors all over India.
Products
- Therapeutic Products
- Animal Products
- Key Products
- Oral Solids
You have 3 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now